References
1. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic
medications in asthma and allergic disease: The next steps toward
personalized care. Vol. 135, Journal of Allergy and Clinical Immunology.
Mosby Inc.; 2015. p. 299–310.
2. BTS/SIGN. British guideline for the management of asthma, SIGN 158,
July 2019. Available from:
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/.
Accessed November 1, 2020.
3. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF,
et al. Efficacy and safety of a recombinant anti-immunoglobulin E
antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy.
2004;34(4):632–8.
4. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et
al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic
Asthma. N Engl J Med. 2014 Sep 25;371(13):1189–97.
5. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A,
et al. Mepolizumab Treatment in Patients with Severe Eosinophilic
Asthma. N Engl J Med. 2014 Sep 25;371(13):1198–207.
6. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al.
Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre,
double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.
7. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe
P, et al. External validity of randomised controlled trials in asthma:
To whom do the results of the trials apply? Thorax. 2007
Mar;62(3):219–33.
8. Richards LB, JMH van Bragt J, Aarab R, Longo C, Neerincx AH, Sont JK,
et al. Treatment Eligibility of Real-Life Mepolizumab-Treated Severe
Asthma Patients. J Allergy Clin Immunol Pract. 2020;8:2999-3008.e1.
9. Brown T, Jones T, Gove K, Barber C, Elliott S, Chauhan A, et al.
Randomised controlled trials in severe asthma: Selection by phenotype or
stereotype. Eur Respir J. 2018;52(6).
10. Papadopoulos NG, Barnes P, Canonica GW, Gaga M, Heaney L,
Menzies-Gow A, et al. The evolving algorithm of biological selection in
severe asthma. Allergy Eur J Allergy Clin Immunol. 2020;75(7):1555–63.
11. Azim A, Mistry H, Freeman A, Barber C, Newell C, Gove K, et al.
Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): A
pragmatic real-life longitudinal study of difficult asthma in the
clinic. BMC Pulm Med. 2019;19(1).
12. BTS/SIGN. British guideline for the management of asthma, SIGN 153,
September 2016. Available from:
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/.
Accessed November 1, 2020.
13. Excellence NIoC. Omalizumab for treating severe persistent allergic
asthma. Technology appraisal guidance. NICE; 2013.
https://www.nice.org.uk/guidance/ta278. Accessed November 1, 2020.
14. Excellence NIoC. Mepolizumab for treating severe refractory
eosinophilic asthma. Technology appraisal guidance. NICE; 2017.
https://www.nice.org.uk/guidance/ta431. Accessed November 1,2020.
15. Azim A, Freeman A, Lavenu A, Mistry H, Haitchi HM, Newell C, et al.
New Perspectives on Difficult Asthma; Sex and Age of Asthma-Onset Based
Phenotypes. J Allergy Clin Immunol Pract. 2020 Nov 1;
16. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J.
The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in
allergic asthma. Respir Med. 2013 Aug 1;107(8):1141–51.
17. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe
A, et al. ‘Real-life’ effectiveness of omalizumab in patients with
severe persistent allergic asthma: The PERSIST study. Respir Med. 2009
Nov 1;103(11):1633–42.
18. Bousquet J, Rao S, Manga V. Global evaluation of treatment
effectiveness (GETE) is an accurate predictor of response to omalizumab
in patients with severe allergic asthma: A pooled analysis. Eur Respir
J. 2014;44(Suppl 58).
19. Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, et al.
Efficacy and safety of treatment with biologicals (benralizumab,
dupilumab and omalizumab) for severe allergic asthma: A systematic
review for the EAACI Guidelines - recommendations on the use of
biologicals in severe asthma. Allergy Eur J Allergy Clin Immunol.
2020;75(5):1043–57.
20. Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’
effectiveness studies of omalizumab in adult patients with severe
allergic asthma: systematic review. Allergy. 2016 May 1;71(5):593–610.
21. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, et
al. Omalizumab in patients with severe asthma: The XCLUSIVE study. Clin
Respir J. 2012 Oct;6(4):215–27.
22. Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, et
al. Oral corticosteroid sparing with omalizumab in severe allergic
(IgE-mediated) asthma patients. Curr Med Res Opin. 2011
Nov;27(11):2223–8.
23. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al.
Predicting and evaluating response to omalizumab in patients with severe
allergic asthma. Respir Med. 2007 Jul 1;101(7):1483–92.
24. Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C,
et al. One year of mepolizumab. Efficacy and safety in real-life in
Italy. Pulm Pharmacol Ther. 2019;58(May).
25. Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A,
et al. Mepolizumab effectiveness and identification of super-responders
in severe asthma. Vol. 55, European Respiratory Journal. 2020.
26. Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L,
et al. Real-World Effectiveness and the Characteristics of a
“Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma. Chest.
2020;158(2):491–500.
27. Darcey J, Qualtrough A. DIFFICULT-TO-TREAT & SEVERE ASTHMA in
adolescent and adult patients - diagnosis and management. Glob Initiat
Asthma. 2019;214(10):493–509.
28. De Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really
different?
29. Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A,
et al. Effectiveness of Omalizumab in Severe Allergic Asthma: A
Retrospective UK Real-World Study. J Asthma. 2013 Jun 14;50(5):529–36.
30. MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I.
Short- and long-term real-world effectiveness of omalizumab in severe
allergic asthma: systematic review of 42 studies published 2008-2018.
Vol. 15, Expert Review of Clinical Immunology. Taylor and Francis Ltd;
2019. p. 553–69.
31. Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW,
et al. Baseline blood eosinophil count as a predictor of treatment
response to the licensed dose of mepolizumab in severe eosinophilic
asthma. Respir Med. 2019 Nov 1;159.
32. Burke H, Davis J, Evans S, Flower L, Tan A, Kurukulaaratchy RJ. A
multidisciplinary team case management approach reduces the burden of
frequent asthma admissions. ERJ Open Res. 2016 Jul 7;2(3).
33. Matcham F, Davies R, Hotopf M, Hyrich KL, Norton S, Steer S, et al.
The relationship between depression and biologic treatment response in
rheumatoid arthritis: An analysis of the British Society for
Rheumatology Biologics Register. Rheumatology. 2018;57:835–43.
34. Vargas PA. Spreading the Word: Comorbidity of Asthma and Depression
Is Not Just the Product of a Vulnerable Personality. Vol. 8, Journal of
Allergy and Clinical Immunology: In Practice. American Academy of
Allergy, Asthma and Immunology; 2020. p. 208–9.
35. González-Freire B, Vázquez I, Pértega-Díaz S. The Relationship of
Psychological Factors and Asthma Control to Health-Related Quality of
Life. J Allergy Clin Immunol Pract. 2020 Jan 1;8(1):197–207.
36. Wang G, Zhou T, Wang L, Wang L, Fu JJ, Zhang HP, et al. Relationship
between current psychological symptoms and future risk of asthma
outcomes: A 12-month prospective cohort study. J Asthma. 2011
Dec;48(10):1041–50.
37. Ahmedani BK, Peterson EL, Wells KE, Williams LK. Examining the
relationship between depression and asthma exacerbations in a
prospective follow-up study. Psychosom Med. 2013;75(3):305–10.
38. Jiang M, Qin P, Yang X. Comorbidity between depression and asthma
via immune-inflammatory pathways: A meta-analysis. Vol. 166, Journal of
Affective Disorders. Elsevier; 2014. p. 22–9.
39. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al.
A Meta-Analysis of Cytokines in Major Depression. Biol Psychiatry. 2010
Mar 1;67(5):446–57.
40. Brown ES, Sayed N, Van Enkevort E, Kulikova A, Nakamura A, Khan DA,
et al. A Randomized, Double-Blind, Placebo-Controlled Trial of
Escitalopram in Patients with Asthma and Major Depressive Disorder. J
Allergy Clin Immunol Pract. 2018 Sep 1;6(5):1604–12.
41. Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC,
et al. Evaluation of Potential Continuation Rules for Mepolizumab
Treatment of Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract.
2018 May 1;6(3):874-882.e4.